Carolyn Busby
Corneal and Contact Management · New York, NYNPI 1497874697
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alcon at 25.3% of the total. Reporting peaked in 2024 at $579 and has fallen 89.6% since, to $60 in 2025. That places this record below the midpoint for corneal and contact management clinicians in NY, where the typical reported total is $933.
Across 22 payments — averaging $53.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$300
- Amgen$210
- Coopervision Inc.$210
- LKC Technologies, Inc.$182
- Topcon Healthcare, Inc.$107
- Maculogix, Inc.$95
- plus $79 from 2 others
What the payments were for
- Food & beverage$1,16598%
- Gifts$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 2 | $300 |
| Amgen(2 entities) | 8 | $210 |
| Coopervision Inc. | 3 | $210 |
| LKC Technologies, Inc. | 2 | $182 |
| Topcon Healthcare, Inc. | 1 | $107 |
| Maculogix, Inc. | 2 | $95 |
| Tarsus Pharmaceuticals, Inc. | 3 | $60 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES TOTAL1$218
How this compares
$1,185 in reported general payments places this provider in the 50th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 45 | $13,680 |
| RestasisCyclosporine | 14 | $8,411 |
| Brimonidine Tartrate | 109 | $5,935 |
| Latanoprost | 297 | $4,142 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 205 | $2,736 |
| Azelastine Hcl | 62 | $707 |
| Cromolyn Sodium | 23 | $291 |
| Dorzolamide Hcl | 21 | $228 |
| Timolol Maleate | 15 | $209 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in New York
- Kevin RosinNew York$59K
- Kevork NiksarliNew York$27K
- Christina ChernyNew York$5K
- Nadine EisenbergNew York$4K
- Traci GoldsteinNew York$4K
- Ralph GundelNew York$3K
- James SinowayNew York$3K
- Jennifer leNew York$3K
- Cynthia ZaraNew York$2K
- Frederic NevinsNew York$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.